^ Jump up to: a b c This paper begins with a history of hemp use and then describes how hemp was constructed as a dangerous crop in the U.S. The paper then discusses the potential of hemp as an alternative crop. Luginbuhl, April M. (2001). "Industrial hemp (Cannabis sativa L): The geography of a controversial plant". The California Geographer (PDF). 41. California Geographical Society. pp. 1–14. Retrieved 2013-03-28. Hemp contains less than 1% THC, or tetrahydrocannabinols, the psychoactive property in marijuana. In other words, smoking hemp cannot create a 'high.' ... The dense growth of hemp eliminates other weeds.... The best growing technique for hemp, planting 300 to 500 plants per square meter, also helps authorities easily tell the hemp from marijuana, which is a plant that is less densely cultivated. (Roulac 1997; 149).
Fibres are obtained by subjecting the stalks to a series of operations—including retting, drying, and crushing—and a shaking process that completes separation from the woody portion, releasing the long, fairly straight fibre, or line. The fibre strands, usually over 1.8 metres (5.8 feet) long, are made of individual cylindrical cells with an irregular surface. The fibre, longer and less flexible than flax, is usually yellowish, greenish, or a dark brown or gray and, because it is not easily bleached to sufficiently light shades, is rarely dyed. It is strong and durable and is used for cordage—e.g., twine, yarn, rope, cable, and string—and for artificial sponges and such coarse fabrics as sacking (burlap) and canvas. In Italy some hemp receives special processing, producing whitish colour and attractive lustre, and is used to make fabric similar to linen.
The cultivation of hemp in the EU is heavily weighted toward fiber production over oilseed production. In 1999, the EU produced about 27,000 t of hemp fiber, but only about 6,200 t of hemp seeds, mostly in France, and 90% of this was used as animal feed (Karus et al. 2000). The seeds (Fig. 33) have traditionally been employed as bird and poultry feed, but feeding the entire seeds to livestock has been considered to be a poor investment because of the high cost involved (although subsidization in Europe allows such usage, especially in France where hemp seeds are not legally permitted in human food). As pointed out later, higher yield and better harvesting practices may make whole hempseed an economical livestock feed. Moreover, seed cake left after expressing the oil is an excellent feed. Efforts are underway in Europe to add value in the form of processed products for hemp, especially cosmetics and food but, as noted below, the North American market is already quite advanced in oilseed applications.
Former President Barack Obama defined industrial hemp as a distinct crop from marijuana in the 2014 U.S. Farm Bill, authorizing higher education institutions and state agricultural departments to give the green light to "regulate and conduct research and pilot programs." But with its classification as a Schedule 1 drug still in effect, the path toward cultivating industrial hemp hasn't been an easy one.
Several of the cannabinoids are reputed to have medicinal potential: THC for glaucoma, spasticity from spinal injury or multiple sclerosis, pain, inflammation, insomnia, and asthma; CBD for some psychological problems. The Netherlands firm HortaPharm developed strains of Cannabis rich in particular cannabinoids. The British firm G.W. Pharmaceuticals acquired proprietary access to these for medicinal purposes, and is developing medicinal marijuana. In the US, NIH (National Institute of Health) has a program of research into medicinal marijuana, and has supplied a handful of individuals for years with maintenance samples for medical usage. The American Drug Enforcement Administration is hostile to the medicinal use of Cannabis, and for decades research on medicinal properties of Cannabis in the US has been in an extremely inhospitable climate, except for projects and researchers concerned with curbing drug abuse. Synthetic preparations of THC—dronabinol (Marinol®) and nabilone (Cesamet®)—are permitted in some cases, but are expensive and widely considered to be less effective than simply smoking preparations of marijuana. Relatively little material needs to be cultivated for medicinal purposes (Small 1971), although security considerations considerably inflate costs. The potential as a “new crop” for medicinal cannabinoid uses is therefore limited. However, the added-value potential in the form of proprietary drug derivatives and drug-delivery systems is huge. The medicinal efficacy of Cannabis is extremely controversial, and regrettably is often confounded with the issue of balancing harm and liberty concerning the proscriptions against recreational use of marijuana. This paper is principally concerned with the industrial uses of Cannabis. In this context, the chief significance of medicinal Cannabis is that, like the issue of recreational use, it has made it very difficult to rationally consider the development of industrial hemp in North America for purposes that everyone should agree are not harmful.
In the early 1990s, industrial hemp agriculture in North America began with the Hemp Awareness Committee at the University of Manitoba. The Committee worked with the provincial government to get research and development assistance, and was able to obtain test plot permits from the Canadian government. Their efforts led to the legalization of industrial hemp (hemp with only minute amounts of tetrahydrocannabinol) in Canada and the first harvest in 1998.
In 1937, the U.S. Treasury Department introduced the Marihuana Tax Act. This Act imposed a levy of $1 per ounce for medicinal use of Cannabis and $100 per ounce for nonmedical use. Physicians in the United States were the principal opponents of the Act. The American Medical Association (AMA) opposed the Act because physicians were required to pay a special tax for prescribing Cannabis, use special order forms to procure it, and keep special records concerning its professional use. In addition, the AMA believed that objective evidence that Cannabis was harmful was lacking and that passage of the Act would impede further research into its medicinal worth. In 1942, Cannabis was removed from the U.S. Pharmacopoeia because of persistent concerns about its potential to cause harm.[2,3]
Cannabis lowers the pressure in the eye that causes optic nerve damage leading to glaucoma. Research has shown conclusively that marijuana users experience lower internal eye pressure while the body metabolizes THC. However, the psychoactive side effects of using THC to treat glaucoma make cannabis a nonviable medication for most people with the disease.
Of course, the easiest solution, advocates say, is for the federal government to legalize cannabis completely. If cannabis were legalized—the whole plant and all its extracts, no confusing singling-out of specific compounds or anatomical features—then U.S. drug companies would be able to carefully cultivate and research its medicinal properties, and submit their findings to regulatory bodies like the FDA for trials and approval.
The applicant, including all corporate officers, must be fingerprinted at a law enforcement agency. The law enforcement agency, not the applicant, must send the fingerprint sheet to the Department (80-18-103, MCA). Most local law enforcement offices provide fingerprinting services. The completed application and copy of the law enforcement submitted fingerprints will be submitted for DEA review and approval. The DEA may place additional requirements on the Department or the applicant for participation or continuation of the program. At the end of the licensure, program participants must submit an agricultural/agronomic report regarding their experience with their hemp crop. The report shall include the approximate yield in pounds per acre and the method used to devitalize the seed. All seed must be devitalized after harvest and no seed production for future planting is allowed under the Montana Industrial Hemp Pilot Program.
Professors William Emboden, Loran Anderson, and Harvard botanist Richard E. Schultes and coworkers also conducted taxonomic studies of Cannabis in the 1970s, and concluded that stable morphological differences exist that support recognition of at least three species, C. sativa, C. indica, and C. ruderalis. For Schultes, this was a reversal of his previous interpretation that Cannabis is monotypic, with only a single species. According to Schultes' and Anderson's descriptions, C. sativa is tall and laxly branched with relatively narrow leaflets, C. indica is shorter, conical in shape, and has relatively wide leaflets, and C. ruderalis is short, branchless, and grows wild in Central Asia. This taxonomic interpretation was embraced by Cannabis aficionados who commonly distinguish narrow-leafed "sativa" strains from wide-leafed "indica" strains.
A 2015 review found that the use of high CBD-to-THC strains of cannabis showed significantly fewer positive symptoms such as delusions and hallucinations, better cognitive function and both lower risk for developing psychosis, as well as a later age of onset of the illness, compared to cannabis with low CBD-to-THC ratios. A 2014 Cochrane review found that research was insufficient to determine the safety and efficacy to using cannabis to treat schizophrenia or psychosis. As of 2017, the molecular mechanisms for the anti-inflammatory and possible pain relieving effects of cannabis are under preliminary research.
Cannabis , also known as marijuana, originated in Central Asia but is grown worldwide today. In the United States, it is a controlled substance and is classified as a Schedule I agent (a drug with a high potential for abuse, and no currently accepted medical use). The Cannabis plant produces a resin containing psychoactive compounds called cannabinoids, in addition to other compounds found in plants, such as terpenes and flavonoids. The highest concentration of cannabinoids is found in the female flowers of the plant. Clinical trials conducted on medicinal Cannabis are limited. The U.S. Food and Drug Administration (FDA) has not approved the use of Cannabis as a treatment for any medical condition. To conduct clinical drug research with Cannabis in the United States, researchers must file an Investigational New Drug (IND) application with the FDA, obtain a Schedule I license from the U.S. Drug Enforcement Administration, and obtain approval from the National Institute on Drug Abuse.